/
Gastroenterology
Fatty Liver Disease
27
Pipeline Programs↗
39
Active Trials↗
43
Companies Involved↗
Fatty Liver Disease is an emerging landscape with 27 programs across 43 companies. The most active players are Innovent Biologics (Suzhou) Co. Ltd., Hudson Biotech. 5 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical14
Phase 27
Phase 35
Approved
No programs
Analysis
Modality Breakdown
80%
Small molecule
20 of 25 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 25 classified programs, each share of the total. Modality classified for 100% of 27 pipeline programs.
Analysis
Trial Status
208
clinical trials
Completed113 · 54%
Recruiting24 · 12%
Unknown status24 · 12%
Terminated21 · 10%
Withdrawn11 · 5%
Active, not recruiting7 · 3%
Other8 · 4%
Clinical Trials
Trial Activity
208 trials
Quantitation of Hepatic Mitochondrial Fluxes in Humans With Nonalcoholic Fatty Liver Disease (NAFLD)
Recruiting·TThe University of Texas Health Science Center at San Antonio·Approved·NCT05305287·60 enrolled
Page 1 of 14
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)